Bayer to Add New Kapitel Report to NextRNA Therapeutics – Action Analysis (The Action)

Kulmbach (www.aktiencheck.de) – Bayer-Aktienanalysis of “Der Aktionär”:

Michel Doepke vom Anlegermagazin “Der Aktionär” nimmt de Aktie der Bayer AG (ISIN: DE000BAY0017, WKN: BAY001, Ticker-Symbol: BAYN, NASDAQ OTC-Symbol: BAYZF) in an active Aktienanalyse under de Lupe.

The Research Area of ​​Oncology Medicine in the Pharma Division of Bayer has a high value. No wonder, which as an innovative Krebstherapies the fortschritte in the back-to-back years has never experienced enormous. With NextRNA Therapeutics, liver function can have another Kapitel effect.

Bayer has made a strategic analysis with the biotech companies of the new molecular technology that does not contain long-term new RNAs (lncRNAs) in oncology vereinbart. The deal is still in two programs. NextRNA has reached a value of 547 Million Dollars, which has found another preliminary and short-term bonus payments. The Americans have taken the trouble to respond to the net allocation.

“With NextRNA’s extensive expertise and lncRNA platform, the novel molecular therapies will open up a new class of diseases in oncology,” said Jürgen Eckhardt, Leader of Business Development & Licensing at Bayer’s Pharma Division. This partnership would have transformed the industry and set a number of oncology pipelines in the industry, Eckhardt continues.

The Entwicklungen of NextRNA are no longer played in one of the most popular stadiums. When the Wirkstoffe, when Bayer went through the deal, the market could last a long time, it was not even in the country where it happened.

A more exciting deal from Bayer, which could not solve the problem of the companies. The company continues with a high net financial debt and a long legal battle. It is possible that Bayer offers with new products the possibility to earn the bestseller Xarelto and Eylea compensations.

Although we had an idea earlier on the Seitenlinie, that is not the case either, so Michel Doepke from “Der Aktionär” at Bayer-Aktie. (Analysis of 28.08.2024)

You can find information about the conflict of interest offensive in the context of Directive 2014/57/EU and the EU statement dissemination under the following link.

Bayer stock exchange promotion:

Tradegate Action Course Bayer Action:
27.42 EUR -0.38% (28.08.2024, 15:12)

XETRA promotions Bayer promotion:
27.43 EUR -0.40% (28.08.2024, 14:59)

ISIN Bayer-Action:
DE000BAY0017

WKN Bayer promotion:
BAY001

Ticker symbol Bayer-Aktie:
BAYN

NASDAQ OTC symbol Bayer-Aktie:
BAYZF

Brief profile Bayer AG:

Bayer (ISIN: DE000BAY0017, WKN: BAY001, Ticker Symbol: BAYN, NASDAQ OTC Symbol: BAYZF) is a Life Science entrepreneur with a prosperous development in general health care and business management. The innovative products will take their legendary discoveries a step further and contribute to another world population. Bayer Helps, promotes, alleviates and heals diseases. Ebenso will offer Bayer a sustainable supply with high-quality food and nutrition products for the production of safe havens – always with the soul, which uses natural resources responsibly. Die Vision des Unternehmens lautet: “Health for all, hunger for none” – Hunger has arisen, a healthy life for all healthy and environmentally friendly people. Dazu will beitragen Bayer and dafür steht der Unternehmenszweck “Science for a better life”. (28.08.2024/ac/a/d)

Opening up of possible interest conflicts:

Conflicts of interest can be found on the site of the counters/of the request for an analysis.